Patents Assigned to Assistance Publique-Hopitaux de Paris
-
Patent number: 10981021Abstract: The present invention relates to a method for transiently disrupting a region of the blood-brain barrier (BBB) of a human using ultrasounds in the presence of an ultrasound contrast agent, and uses thereof. The method comprises the application of at least one ultrasound (US) beam with a pressure level higher than 1 MPa and a resonance frequency ranging from 0.5 to 1.5 MHz.Type: GrantFiled: March 11, 2016Date of Patent: April 20, 2021Assignees: Carthera, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie (Paris 6)Inventors: Alexandre Carpentier, Michael Canney, Alexandre Vignot
-
Publication number: 20210106415Abstract: Device for inspecting the stability of a dental implant (1) in a bone (2), the implant having a free end (1a) and an end (1b) buried in the bone (2). The device comprises an ultrasonic transducer (12) for emitting and collecting an ultrasonic wave reflected from a contact interface (4) between the implant (1) and the bone (2), and providing a measurement signal representing the reflected ultrasonic wave. The device also comprises a processing unit for computing, based on the measurement signal, an indicator (IN) whose value makes it possible to evaluate the integration of the implant (1) into the bone (2). The indicator (IN) corresponds to the average energy of the measurement signal over a time interval (t1-t2) starting at a first time (t1) and ending at a second time (t2). The first time (t1) is between 20 and 80 ?s after the start of the emission of the ultrasonic wave.Type: ApplicationFiled: April 16, 2019Publication date: April 15, 2021Applicants: Centre National de la Recherche Scientifique, UNIVERSITE PARIS XII - VAL DE MARNE, L'ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Guillaume Haiat, Romain Vayron
-
Publication number: 20210093247Abstract: A computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephalographic signal, the method including the steps of obtaining (A) an electroencephalographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero-crossings of the electroencephalographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephalographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephalographic signals; calculating (E) a matching score by comparing the zero-crossing representation of a segment of the electroencephalographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function fromType: ApplicationFiled: March 30, 2018Publication date: April 1, 2021Applicants: BIOSERENITY, ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITEInventors: Jan PYRZOWSKI, Michel LE VAN QUYEN, Jean-Eudes LE DOUGET
-
Patent number: 10960015Abstract: Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.Type: GrantFiled: December 18, 2018Date of Patent: March 30, 2021Assignee: Assistance Publique-Hopitaux De ParisInventors: Stéphane Auvin, Thomas Storme, Pascal Vaconsin, Vincent Boudy
-
Publication number: 20210088483Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the mType: ApplicationFiled: February 21, 2019Publication date: March 25, 2021Applicants: Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite De Paris, Ecole Nationale Superieure de Chimie de ParisInventors: Hugo Salmon, Rabah Gahoual, Nathalie Mignet, Pascal Houze
-
Publication number: 20210085236Abstract: A system for calculating an indicator associated to a brain activity of a subject, the system including an acquisition module configured to acquire at least an epoch of electroencephalographic signal of a subject from a plurality of electrodes and a data processing module configured to carry out the steps of: calculating an average vector (VA) using as input of an autoencoder neural network (aNN) an electroencephalographic signals (ES) of a subject acquired from a plurality of electrodes; detecting (DET) the presence of at least a predefined pattern in the consecutive average values of the average vector (VA); and generating an indicator of brain activity (Idx) of the subject when detecting the predefined pattern.Type: ApplicationFiled: December 21, 2018Publication date: March 25, 2021Applicants: BIOSERENITY, ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÈPINIÈRE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Mohcine HEDDI, Michel LE VAN QUYEN, Jean-Eudes LE DOUGET
-
Patent number: 10948498Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.Type: GrantFiled: August 8, 2014Date of Patent: March 16, 2021Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de LorraineInventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
-
Patent number: 10947598Abstract: Provided is an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Also provided is an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.Type: GrantFiled: September 29, 2016Date of Patent: March 16, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Université Côte d'Azur, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)Inventors: Jean-Ehrland Ricci, Johanna Chiche, Catherine Thieblemont
-
Patent number: 10941448Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: January 11, 2019Date of Patent: March 9, 2021Assignees: The Universite Paris-Saclay, The Assistance Publique-Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM), PML Screening, LLCInventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Publication number: 20210052547Abstract: The present invention relates to a compound of formula (I): wherein: -n is 1 or 2; Z1, Z2 and Z3, identical or different, are selected from a hydrogen atom, a halogen atom and a (C1-C6)alkyl group; and —R is an optionally substituted (C1-C6)alkyl group by one or more substituents chosen from a hydroxyl, an oxo and a thiol group; or one of its pharmaceutically acceptable salts; for use to decrease urinary oxalate concentration in an individual. The present invention further relates to a compound of formula (I) for use in the prevention and/or treatment of diseases and/or conditions related to a high urinary oxalate concentration in an individual.Type: ApplicationFiled: February 14, 2017Publication date: February 25, 2021Applicants: Institut National de la Sante et de la Recherche Medicale (NSERM), Assistance Publique-Hopitaux de Paris, Sorbonne UniversiteInventors: Emmanuel Letavernier, Michel Daudon
-
Publication number: 20210038691Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: ApplicationFiled: July 10, 2020Publication date: February 11, 2021Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITEInventors: David Klatzmann, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
-
Publication number: 20210041457Abstract: The invention relates to a non-invasive process for evaluating the quality of one or more dense connective tissue(s) in a patient, comprising the following steps: a) Analyzing the profile of the microrelief of a cutaneous replica of a portion of the skin of said patient by at least one of the following step: a1. visually assessing on picture(s) of said cutaneous replica the line shape and the anisotropy of the lines; and/or a2. Determining, on picture(s) of said cutaneous replica, the roughness index of the microrelief with an optical sensor, b) identifying cutaneous replica of “stage 1”, representative of healthy skins, and cutaneous replica of “stage 2” representative of altered skins, a cutaneous replica of stage 2 being indicative of low quality of the one or more dense connective tissue(s) in the patients body.Type: ApplicationFiled: September 24, 2018Publication date: February 11, 2021Applicants: ECOLE CENTRALE DE LYON, UNIVERSITE PARIS-SACLAY, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Thierry HOC, Jean-Charles AUREGAN, Morad BENSIDHOUM, Catherine BOSSER, Hassan ZAHOUANI
-
Publication number: 20210040563Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.Type: ApplicationFiled: January 25, 2019Publication date: February 11, 2021Applicants: SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURSInventors: Olivier CUSSENOT, Aurélie KAMOUN, Aurélien DE REYNIES, Géraldine CANCEL-TASSIN, Gaëlle FROMONT-HANKARD
-
Publication number: 20210030703Abstract: In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.Type: ApplicationFiled: March 11, 2019Publication date: February 4, 2021Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE PARIS, SORBONNE UNIVERSITÉ, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS-SACLAYInventors: Guido KROEMER, Sarah LEVESQUE, Jonathan POL
-
Publication number: 20210022638Abstract: This method for generating an indicator of the state of a patient in coma includes: generating at least one auditory stimulation by generating a sequence of auditory stimuli, the sequence producing evoked potentials in the patient; acquiring a first electroencephalographic signal produced by patient from at least one electrode; estimating at least one pair of values corresponding to a first parameter and a second parameter extracted from the first acquired signal, including estimating a first pair of values such that calculating the first parameter includes an estimation of the amplitude variance of the first signal within a predefined time window and the calculation of the second parameter includes an estimation of the correlation of two segments of the first signal; generating a state indicator for the or each pair of values of the first and second parameters, the values defining coordinates of a point in a reference base.Type: ApplicationFiled: March 22, 2019Publication date: January 28, 2021Applicants: PARIS SCIENCES ET LETTRES - QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, ÉCOLE NORMALE SUPÉRIEURE, UNIVERSITÉ DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: David HOLCMAN, Adrien DOUMERGUE, Nathalie KUBIS, Alexandra RICHARD, Aymeric FLOYRAC
-
Patent number: 10874637Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration in with brain iron accumulation (NBIA). Studying two novel genes, namely, CRAT encoding the carnitine acetyltransferase and REPS1 involved in endocytosis and vesicle transport, and a series of known NBIA genes, the inventors reported on iron overload related to increased levels and abnormal recycling of transferrin receptor as a common feature in NBIA. They ascribe this anomaly, at least in part, to impaired palmitoylation of the receptor as a common consequence of the various disease causing mutations. Finally, the inventors show that Artesunate improved TfR1 palmitoylation in NBIA fibroblasts. In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation.Type: GrantFiled: December 19, 2017Date of Patent: December 29, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DESCARTES, FONDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Anne Agnès Rötig, Anthony Drecourt
-
Publication number: 20200390817Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: ApplicationFiled: September 2, 2020Publication date: December 17, 2020Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen
-
Publication number: 20200383973Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.Type: ApplicationFiled: July 21, 2020Publication date: December 10, 2020Applicants: Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne UniversiteInventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
-
Publication number: 20200353072Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: July 23, 2020Publication date: November 12, 2020Applicants: DBV Technologies, Assistance Publique Hopitaux De Paris, Universite Paris DescartesInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Publication number: 20200347121Abstract: The present invention provides a medicament comprising as active ingredient an inhibitor of Coll2-1 peptide activity and/or an inhibitor of Coll2-1NO2 peptide activity for use in the prevention and/or treatment of osteoarthritis. Further, the present invention provides a medicament comprising as active ingredient an inhibitor of Coll2-1 peptide activity and/or an inhibitor of Coll2-1NO2 peptide activity for use in the prevention and/or treatment of rheumatic and musculoskeletal diseases (RMDs).Type: ApplicationFiled: May 4, 2020Publication date: November 5, 2020Applicants: Université de Liège, Université Paris Descartes, Assistance Publique Hopitaux de Paris, Institut National de la Santé et de la Recherche MédicaleInventors: Yves HENROTIN, Cécile LAMBERT, Didier BORDERIE, François RANNOU